Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia

Nexalin Technology announced the issuance of U.S. Patent No. 12,629,519 covering transcranial alternating current dynamic frequency stimulation methods for anxiety, depression, and insomnia, providing intellectual property protection through 2042. The patent strengthens the company's competitive position in non-invasive deep-brain neurostimulation and supports its HALO™ Clarity platform and Nexalin NeuroCare™ virtual clinic strategy.